Piramal Pharma has reported a 22.6% reduction in Scope 1 [...]
Collaboration targets faster, lower-cost production of RNA-based therapies with reduced [...]
Piramal Pharma has reported a 22.6% reduction in Scope 1 [...]
Collaboration targets faster, lower-cost production of RNA-based therapies with reduced [...]